de la Fouchardière C
Département de cancérologie médicale, Centre Léon-Bérard, 28, rue Laennec, 69373 Lyon, Cedex 08, France.
Ann Endocrinol (Paris). 2015 Feb;76(1 Suppl 1):1S34-9. doi: 10.1016/S0003-4266(16)30012-9.
Radio-iodine refractory metastatic thyroid cancers are rare and their management was until recently relatively complex. New therapeutic agents, kinase inhibitors, joined since the early 2000s the fight against these cancers with very promising results. These targeted agents showed for two of them (sorafenib; lenvatinib), in randomized phase III trials, a significant improvement in response rate and progressionfree survival when compared to placebo, leading to the first approval for radio-iodine refractory metastatic thyroid cancers. In parallel, patients also benefited from the development of interventional radiology techniques and organization of cares in oncology, with multidisciplinary management strengthened by the creation of a national network (TUTHYREF).
放射性碘难治性转移性甲状腺癌较为罕见，直到最近其治疗仍相对复杂。自21世纪初以来，新型治疗药物——激酶抑制剂加入了对抗这些癌症的斗争，并取得了非常有前景的成果。其中两种靶向药物（索拉非尼；仑伐替尼）在随机III期试验中显示，与安慰剂相比，其缓解率和无进展生存期有显著改善，从而首次获批用于放射性碘难治性转移性甲状腺癌。与此同时，患者也受益于介入放射学技术的发展和肿瘤学护理的组织安排，通过建立全国性网络（TUTHYREF）加强了多学科管理。
